|Description||GSK2879552 has been found to be a LSD1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells. It was just planed a Phase I/II trail by GSK against Myelodysplastic syndromes.|
|Synonyms||GSK2879552; UNII-GT77Z6Y09Z; GSK-2879552; GSK 2879552; GT77Z6Y09Z; 1401966-69-5; 4-((4-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid|
|Solubility||DMSO: 31 mg/mL|
|Application||GSK2879552 has been found to be a LSD1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
NCGC00244536 is a potent KDM4A inhibitor (IC50= 10 nM) that inhibits the in vivo growth of tumors derived from PC3 cells and ex vivo human PCa explants.
SP2509 inhibits the association of LSD1 with CoREST, increases promoter-specific H3K4Me3 and induces p53, p21 and C/EBPα. SP2509 also significantly inhibits the...
KDM5-inhibitor is an analog of CPI-455, a selective KDM5 inhibitor. CPI-455 increases levels of H3K4 trimethylation (H3K4me3) and decreases the number of DTPs i...
(Z)-JIB-04 is a Z-isomer of JIB-04, which is a small-molecule histone demethylase inhibitor with antitumor activity. JIB-04 selectively inhibits tumor growth vi...
CPI 455 is a selective inhibitor of KDM5 demethylases (IC50 value 10 nM for inhibition of full length KDM5A) that specifically alters H3K4 methylation (H3K4me3)...
ML324 exhibits good Caco-2 cell permeability, and possesses excellent microsomal stability in the presence of both mouse and rat liver microsomes.
KDM5-IN-1 is a potent and selective KDM5 inhibitor with modest cell activity (PC9 H3K4Me3 EC50 = 5.2 μM).
GSK3326595, also called as EPZ015938, is an orally available and specific inhibitor of protein arginine methyltransferase 5 (PRMT5) that potently inhibits tumor...